dihydromicrocystin LR: cyclic heptapeptide hepatotoxin from the cyanobacterium Microcystis aeruginosa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6441227 |
| MeSH ID | M0178808 |
| Synonym |
|---|
| 1-(n-methyl-d-alanine)-5-l-argininemicrocystin la |
| (d-meala7)microcystin-lr |
| microcystin la, 1-(n-methyl-l-alanine)-5-l-arginine- |
| 1-(n-methyl-l-alanine)-5-l-argininemicrocystin la |
| (l-meala7)microcystin-lr |
| microcystin la, 1-(n-methyl-d-alanine)-5-l-arginine- |
| dihydromicrocystin lr |
| 15-[3-(diaminomethylideneamino)propyl]-18-[(1e,3e)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,2,5,12,19-pentamethyl-8-(2-methylpropyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic acid |
| 146145-26-8 |
| 146145-25-7 |
| dihydromicrocystin-lr |
| cyanoginosin la, 1-(n-methyl-dl-alanine)-5-l-arginine- |
| cyclo(ala-leu-beta-methyl-asp-arg-adda-glu-n-methyldehydro-ala) |
| 129678-94-0 |
| cyclo(alanyl-leucyl-beta-methyl-aspartyl-arginyl-(3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid)-glutamyl-n-methyldehydroalanyl) |
| DTXSID801339234 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The two stereoisomers of both dihydronodularin (2 and 3) and dihydromicrocystin-LR (5 and 6), isolated by reversed-phase HPLC, showed similar toxicity to each other [ip in mice, LD50 = 150 (2), 150 (3), 85 (5), and 100 (6) micrograms/kg]." | ( Chemical characterization and toxicity of dihydro derivatives of nodularin and microcystin-LR, potent cyanobacterial cyclic peptide hepatotoxins. Carmichael, WW; Choi, BW; Evans, WR; Namikoshi, M; Rinehart, KL; Sun, F, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The livers of both groups dosed at 75 micrograms/kg contained higher concentrations of toxin, but lower percentages of the total dose, than the livers of pigs dosed at 25 micrograms/kg." | ( Distribution of tritiated dihydromicrocystin in swine. Beasley, VR; Choi, BW; Haschek, WM; Rinehart, KL; Stotts, RR; Twardock, AR, 1997) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||